Eli Lilly (LLY) Surpasses Market Returns: Key Performance Metrics and Analyst Estimates

ElmerBusiness2025-06-268870

Eli Lilly (LLY) closed the most recent trading day at $770.64, marking a +1.04% increase from the previous session. The stock's performance outpaced the S&P 500's daily gain of 0.96%, while the Dow rose 0.89% and the Nasdaq increased 0.94%.

High Yield Savings Offers

Investors looking for high-yield savings options can consider the following offers:

Cit Bank: Earn 4.10% APY on balances of $5,000 or more. [View Offer]
Current Bank: Earn up to 4.00% APY with Savings Pods. [View Offer]
Sofi Bank: Earn up to 3.80% APY and a $300 cash bonus with direct deposit. [View Offer]

Performance Overview

Shares of Eli Lilly have gained 6.87% in the past month, outperforming the Medical sector's loss of 0.85% and the S&P 500's gain of 0.5%. Investors and analysts will be closely watching the company's upcoming earnings disclosure, scheduled for August 7, 2025.

Earnings Estimates

The company is expected to report an EPS of $5.56, indicating a 41.84% growth compared to the same quarter last year. Revenue is anticipated to be $14.47 billion, a 28.02% increase from the previous year. For the annual period, the Zacks Consensus Estimates predict earnings of $21.95 per share and revenue of $59.92 billion, representing shifts of +68.98% and +33.03%, respectively, from the previous year.

Analyst Estimates and Zacks Rank

Recent changes to analyst estimates for Eli Lilly often reflect shifting business dynamics. Upward revisions indicate analysts' optimism about the company's operations and profitability. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), provides a simple, actionable rating system based on these estimate changes. Currently, Eli Lilly has a Zacks Rank of #3 (Hold), with a slight decrease in the Zacks Consensus EPS estimate over the past month (-0.61%).

Valuation Metrics

Investors should also consider valuation metrics such as the Forward P/E ratio and PEG ratio. Eli Lilly currently has a Forward P/E ratio of 34.75, which is higher than the average Forward P/E of 13.35 for its industry. The PEG ratio, which takes into account expected earnings growth, is 1.11, compared to the Large Cap Pharmaceuticals industry average of 1.23 at yesterday's closing price.

Industry Rank and Outlook

The Large Cap Pharmaceuticals industry is part of the Medical sector and has a Zacks Industry Rank of 83, placing it in the top 34% of all 250+ industries. The Zacks Industry Rank evaluates industry groups based on the average Zacks Rank of their constituent stocks, with top-rated industries outperforming bottom-rated ones by a factor of 2 to 1.

Investors can stay updated with all these stock-shifting metrics and more by using Zacks.com in their next trading sessions. For more recommendations from Zacks Investment Research, download their free report on Eli Lilly and Company (LLY).